Population differences in vaccine responses (POPVAC): scientific rationale and cross-cutting analyses for three linked, randomised controlled trials assessing the role, reversibility and mediators of immunomodulation by chronic infections in the tropics. by Nkurunungi, Gyaviira et al.
1Nkurunungi G, et al. BMJ Open 2021;11:e040425. doi:10.1136/bmjopen-2020-040425
Open access 
Population differences in vaccine 
responses (POPVAC): scientific 
rationale and cross- cutting analyses for 
three linked, randomised controlled 
trials assessing the role, reversibility 
and mediators of immunomodulation 
by chronic infections in the tropics
Gyaviira Nkurunungi   ,1 Ludoviko Zirimenya,1 Agnes Natukunda,1 
Jacent Nassuuna,1 Gloria Oduru,1 Caroline Ninsiima,1 Christopher Zziwa,1 
Florence Akello,1 Robert Kizindo,1 Mirriam Akello,1 Pontiano Kaleebu,1 Anne Wajja,1 
Henry Luzze,2 Stephen Cose,1,3 Emily Webb,4 Alison M Elliott,1,3 POPVAC trial team
To cite: Nkurunungi G, 
Zirimenya L, Natukunda A, 
et al.  Population differences in 
vaccine responses (POPVAC): 
scientific rationale and cross- 
cutting analyses for three 
linked, randomised controlled 
trials assessing the role, 
reversibility and mediators 
of immunomodulation 
by chronic infections in 
the tropics. BMJ Open 
2021;11:e040425. doi:10.1136/
bmjopen-2020-040425
 ► Prepublication history and 
additional material for this paper 
is available online. To view these 
files, please visit the journal 
online (http:// dx. doi. org/ 10. 
1136/ bmjopen- 2020- 040425).
GN, LZ and AN contributed 
equally.
Received 13 May 2020
Revised 01 October 2020
Accepted 14 November 2020
For numbered affiliations see 
end of article.
Correspondence to
Dr Gyaviira Nkurunungi;  
 Gyaviira. Nkurunungi@ 
mrcuganda. org
Protocol
 ► http:// dx. doi. org/ 10. 1136/ 
bmjopen- 2020- 040426
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY. 
Published by BMJ.
ABSTRACT
Introduction Vaccine- specific immune responses vary 
between populations and are often impaired in low 
income, rural settings. Drivers of these differences are 
not fully elucidated, hampering identification of strategies 
for optimising vaccine effectiveness. We hypothesise that 
urban–rural (and regional and international) differences 
in vaccine responses are mediated to an important extent 
by differential exposure to chronic infections, particularly 
parasitic infections.
Methods and analysis Three related trials sharing 
core elements of study design and procedures (allowing 
comparison of outcomes across the trials) will test 
the effects of (1) individually randomised intervention 
against schistosomiasis (trial A) and malaria (trial B), 
and (2) Bacillus Calmette- Guérin (BCG) revaccination 
(trial C), on a common set of vaccine responses. We will 
enrol adolescents from Ugandan schools in rural high- 
schistosomiasis (trial A) and rural high- malaria (trial B) 
settings and from an established urban birth cohort (trial 
C). All participants will receive BCG on day ‘0’; yellow fever, 
oral typhoid and human papilloma virus (HPV) vaccines at 
week 4; and HPV and tetanus/diphtheria booster vaccine 
at week 28. Primary outcomes are BCG- specific IFN-γ 
responses (8 weeks after BCG) and for other vaccines, 
antibody responses to key vaccine antigens at 4 weeks 
after immunisation. Secondary analyses will determine 
effects of interventions on correlates of protective 
immunity, vaccine response waning, priming versus 
boosting immunisations, and parasite infection status and 
intensity. Overarching analyses will compare outcomes 
between the three trial settings. Sample archives will 
offer opportunities for exploratory evaluation of the role of 
immunological and ‘trans- kingdom’ mediators in parasite 
modulation of vaccine- specific responses.
Ethics and dissemination Ethics approval has 
been obtained from relevant Ugandan and UK ethics 
committees. Results will be shared with Uganda Ministry 
of Health, relevant district councils, community leaders 
and study participants. Further dissemination will be done 
through conference proceedings and publications.
Strengths and limitations of this study
 ► This will be the first well- powered programme 
of work to investigate effects of schistosomiasis 
treatment, of malaria treatment, and of Bacillus 
Calmette- Guérin revaccination on vaccine respons-
es in adolescents.
 ► A major strength of this work is the opportunity to 
synthesise findings from three different study set-
tings with differential parasite exposure using caus-
al mediation analysis to obtain a comprehensive 
understanding of how parasitic infections influence 
vaccine responses in human populations.
 ► The results will provide insight into effects of para-
sites on infectious disease susceptibility: immunisa-
tion, notably with live vaccines, offers a surrogate for 
infection challenge in human subjects.
 ► The sample archives developed will provide a major 
asset for exploration of new leads arising from this 
hypothesis- driven work, or for an alternative, ‘sys-
tems biology’ approach investigating, for example, 
transcriptome, microbiome and virome.
 ► One limitation is that observational analyses of par-
asite effects are subject to potential unmeasured 
confounding; this will be mitigated by cautious in-
terpretation of results and our intervention studies 
will address causality rigorously.
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Trial registration numbers ISRCTN60517191, ISRCTN62041885, 
ISRCTN10482904.
INTRODUCTION
Population differences in vaccine responses
Effective vaccines are key weapons against infectious 
diseases,1 but are still lacking for many poverty- related, 
neglected, emerging and re- emerging infections. Vaccine 
responses vary between populations and are often 
impaired in low income, rural settings.2–6 A notable 
example is Bacillus Calmette- Guérin (BCG): both vaccine 
response and efficacy against tuberculosis differ interna-
tionally3 4 and regionally.6 7 Among other vaccines, yellow 
fever vaccine induced lower neutralising antibody levels, 
and responses waned faster, in Uganda compared with 
Switzerland.5 Oral rotavirus and polio vaccines are also 
affected.2 Within country, influenza and tetanus responses 
differed between urban and rural Gabon.8 9 Responses to 
candidate tuberculosis,10 malaria11 and Ebola12 vaccines 
are lower in Africa than in Europe or America. Prior expo-
sure to the pathogen targeted by the vaccine, or to related 
organisms, may contribute to this phenomenon, but 
recent analyses implicate broader ‘environmental sensiti-
sation’,6 the drivers of which have not been determined. 
Prior exposure cannot explain results for vaccines against 
rare organisms, such as Ebola. Thus, drivers of POPula-
tion differences in VACcine responses (POPVAC) are not 
fully elucidated; improved understanding is important 
for effective vaccine development and implementation.
The POPVAC programme comprises three trials, A, 
B and C, designed to address this challenge. The indi-
vidual trial protocols are presented separately in this 
journal (bmjopen-2020-040426, bmjopen-2020-040427 
and bmjopen-2020-040430). This ‘Protocol X’ provides 
an overview of our hypotheses and objectives.
Immunomodulation by parasitic infections
Parasitic infections are important in tropical low- income 
countries (LICs),13–15 and long proposed as modula-
tors of vaccine responses.16–19 As detailed in POPVAC A 
(bmjopen-2020-040426) and POPVAC B (bmjopen-2020-
040427) protocols, animal models20–22 and observational 
human studies23–25 support this hypothesis, but no well- 
powered trials have been conducted to evaluate causality 
and reversibility of parasite effects on vaccine responses 
in adolescents or adults.26
Trained immunity
Exposure to other unrelated infections or microbial 
antigens may also contribute to ‘environmental sensiti-
sation’, modulating vaccine responses through training 
of the innate immune system.27 BCG immunisation is a 
key model for this effect,28 29 as considered in Protocol C 
(bmjopen-2020-040430).
The ‘transkingdom’ concept
The ‘transkingdom’ concept30 emphasises that mammals 
support a complex ecosystem of multicellular organisms, 
such as helminths, as well as bacteria, fungi, protozoa and 
viruses, and suggests that these interact in their effects 
on the mammalian immune system, rather than acting 
alone, as individual agents.30 For example, in a mouse 
model, infection with the gut helminth Heligmosomoides 
polygyrus, or exposure to schistosome eggs, activated 
latent herpesvirus infection via alternative macrophage 
activation and the IL-4/Stat6 pathway.31 In a contrasting 
study, H. polygyrus caused enhanced responses to respi-
ratory syncytial virus in the mouse lung through interac-
tion with the gut microbiome, translocation of microbial 
products to the circulation and enhanced systemic type 
I interferon expression.32 Interestingly, in these studies, 
the same helminth resulted in opposite outcomes for 
latent viruses (for which it induced activation), versus 
exogenous viruses (for which it improved control).
Little has been done to evaluate these phenomena in 
human populations but, regarding latent herpesviruses 
our studies show that parasite exposure associates with 
elevated Kaposi’s Sarcoma Herpesvirus antibody prev-
alence and titre (indicating viral activation).33–35 The 
impact of malaria on Epstein- Barr virus, promoting induc-
tion of Burkitt’s lymphoma, is well recognised.36 Cyto-
megalovirus has major immunological effects, including 
impact on vaccine responses.37
In humans, evidence of enhanced microbial transloca-
tion (MT) has been found during Schistosoma mansoni,38 
hookworm39 and Strongyloides40 infection, with altered 
expression of parameters such as toll- like receptor 
expression, but without the level of immune activation 
associated with septic shock or with MT in HIV infection. 
Nevertheless, the second mouse model discussed above 
shows that this may have profound effects on responses to 
infectious agents at remote sites.32
Thus, herpesvirus activation and, or, MT may mediate, 
in part, parasite- induced modulation of vaccine responses.
Differences in immunological characteristics between 
populations
Whatever the key exposures and mechanisms involved, 
immunological characteristics differ markedly between 
populations internationally,5 41 42 and between urban and 
rural settings.41 43 44 Characteristics that differ include 
gene methylation and expression (not solely attribut-
able to population genetics)43 45; responses to innate 
stimuli42 45; frequency and activation of innate immune 
cells, T and B cells, and memory cell pools.5 41 Under-
standing the immunological predictors of vaccine 
response, and factors that drive them, will contribute to 
strategies for improving vaccine efficacy for rural, tropical 
settings.
HYPOTHESIS AND OBJECTIVES
The overarching goal of the ‘POPVAC’ is to understand 
POPVAC, in order to identify strategies through which 
vaccine effectiveness can be optimised for low income, 
tropical settings where they are especially needed. We 
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focus on the hypothesis (figure 1) that geographical 
differences in vaccine responses are mediated to an 
important extent by differential exposure to chronic, 
particularly parasitic, infections; that parasites act in 
part via ‘transkingdom’ effects; and that these exposures 
impact the preimmunisation immune profile and hence 
vaccine response (and efficacy).
We will address this hypothesis in three, linked trials 
(POPVAC A, B and C; detailed protocols published sepa-
rately in this journal: bmjopen-2020-040426, bmjopen-
2020-040427 and bmjopen-2020-040430, respectively) 
which share core elements of study design and proce-
dures, allowing comparison of outcomes across the trials. 
Each trial will test effects of a different randomised inter-
vention on a common set of vaccine responses. POPVAC 
A will determine the effect of intensive schistosomiasis 
treatment on vaccine responses among rural island 
adolescents. POPVAC B will determine the effect of inten-
sive malaria treatment on vaccine responses among rural 
adolescents. POPVAC C will determine the effect of BCG 
revaccination on responses to unrelated vaccines.
This paper describes background and methods 
common to all three trials, summarises objectives linking 
the trials, and details planned approaches to cross- cutting 
objectives which will use data and samples from all trials. 
Standard Protocol Items: Recommendations for Inter-
ventional Trials reporting guidelines46 are used.
Our objectives are to
1. Determine whether there are reversible effects of 
chronic parasitic infection on vaccine response 
(POPVAC A and B).
2. Determine whether BCG ‘preimmunisation’ enhances 
responses to unrelated vaccines (POPVAC C).
3. Determine which life- course exposures influence 
vaccine responses in adolescence (using data from 
POPVAC C).
4. Compare vaccine response profiles between three 
Ugandan settings (using data from all trials): rural, 
Figure 1 Hypothesised pathways to population differences in vaccine responses.
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high schistosomiasis exposure; rural, high malaria ex-
posure and urban.
5. Explore the role of ‘transkingdom’ interactions in de-
termining vaccine responses (using samples and data 
from all Trials).
6. Investigate preimmunisation immunological parame-
ters associated with vaccine responses and determine 
whether these are driven by parasite or microbial expo-
sure (using samples and data from all trials).
METHODS AND ANALYSIS
Setting
Uganda still experiences high schistosomiasis47 48 and 
malaria burdens.49–51 Our study sites (figure 2) will 
be Lake Victoria Koome Islands (high schistosomi-
asis),47 52 Jinja district rural subcounties (high malaria)51 
and Entebbe (urban; low schistosomiasis and low 
malaria).52 These settings provide ideal opportunities 
to investigate effects of schistosomiasis and malaria on 
vaccine responses. Geohelminths are less common in our 
settings47 53: hookworm, especially, has declined dramat-
ically following government intervention programmes; 
therefore, geohelminths will be considered as potential 
confounders, where appropriate, but not prioritised.
Cohorts
This work will involve adolescents from two rural settings 
and one urban cohort (figure 3). Rural trials will recruit 
participants aged 9–17 years from primary schools in 
Koome islands (POPVAC A) and Jinja district (POPVAC 
B), selected purposefully to assure schistosomiasis and 
malaria prevalence appropriate to our design. This will 
allow us to investigate our two major infections separately, 
averting the risk that a potent effect of one infection 
masks an impact of the other, or of its treatment.
POPVAC C will recruit members of the Entebbe 
Mother and Baby Study (EMaBS) birth cohort54: 2500 
women were recruited between 2003 and 2005 in a trial 
of anthelminthic treatment during pregnancy, investi-
gating effects on infants’ vaccine responses.54 Children 
from the EMaBS birth cohort will be aged 13 to 17 years 
during recruitment to this study; about 300 individuals 
are expected to take part.
Interventions
In the high- schistosomiasis cohort (trial A), we will indi-
vidually randomise participants to intensive or standard 
praziquantel (PZQ) treatment, in a 1:1 ratio, in an open- 
label, parallel group trial.
In the high- malaria cohort (trial B), we will individu-
ally randomise participants to monthly dihydroartemis-
inin piperaquine (DP) versus placebo in a double- blind, 
placebo- controlled trial.
In the urban (EMaBS) cohort (trial C), we will individ-
ually randomise participants to BCG revaccination, or no 
BCG revaccination, as the first component of the vaccine 
schedule, in a controlled, open- label, parallel- group trial.
Recruitment criteria, interventions, randomisation and 
treatment allocation procedures are detailed in protocols 
for trials A, B and C (bmjopen-2020-040426, bmjopen-
2020-040427 and bmjopen-2020-040430, respectively; 
published in this journal).
Figure 2 Study sites.
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Immunisations
We have previously highlighted the complexity of 
helminth effects on vaccine responses.26 Differences 
in parasite effects on live and non- live, oral and paren-
teral, priming and boosting vaccines may contribute to 
this. Activated innate responses may kill live vaccines and 
suppress subsequent adaptive responses,5 55 but bias, or 
enhance, responses to toxoids or proteins17 23 56; intestinal 
inflammation may impair responses to live oral vaccines57; 
priming may be more vulnerable than boosting.58 59 
Thus, results from a single- vaccine study would not be 
generalisable.
Therefore, we will study a portfolio of licensed vaccines 
expected to be beneficial (some already given) to adoles-
cents in Uganda: live parenteral (BCG, yellow fever), 
live oral (typhoid) and non- live (HPV) (a viral particle 
vaccine) and tetanus/diphtheria (Td; toxoid vaccines). 
This will allow us to compare effects of interventions 
and exposures between vaccine types. Each cohort will 
receive the same vaccine portfolio (table 1), comprising 
three main immunisation days (weeks 0, 4 and 28). 
Additional HPV immunisation will be provided for girls 
aged 14 years or above, and a second Td boost will be 
given after study completion, to accord with national 
Expanded Programme on Immunisation (EPI) routines, 
but responses to these will not specifically be addressed. 
Further rationale for vaccine selection is detailed in 
online supplemental material 1. Our schedule has been 
developed in consultation with the EPI programme (see 
online supplemental table 1) and is cognizant of potential 
interference between vaccines (see online supplemental 
material 1, online supplemental table 2).
Although optimal timings for outcome measures vary 
between vaccines, sampling (for primary endpoints) 















Yellow fever (YF- 17D)
Oral typhoid (Ty21a)
      
Non- live 
vaccines
  HPV prime HPV boost for girls 





*All participants in the urban (Entebbe Mother and Baby Study, EMaBS) cohort received BCG at birth, so within EMaBS this will 
berevaccination; prior BCG status may vary for the rural cohorts (data on history and documentation of prior BCG, and presence of a BCG 
scar, will be documented although these approaches have limitations for determining BCG status).
†EMaBS participants will be randomised to receive BCG ‘preimmunisation’ or not as part of trial C.
‡All participants in rural cohorts will receive BCG (trials A and B).
§The National EPI programme recommends three doses of HPV vaccine for older girls.
¶These doses will be given to comply with guidelines but outcomes specifically relating to these doses will not be assessed.
**Priming by immunisation in infancy is assumed.
BCG, bacillus calmette- guérin; HPV, human papilloma virus.
Figure 3 Overall programme design and sample sizes. BCG, bacillus calmette- guérin; DP, dihydroartemisinin.
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will be done at 8 weeks post BCG, 4 weeks post YF- 17D, 
Ty21a, HPV and Td (figure 4), targeting establishment 
of memory responses and antibody response peaks. A 
secondary endpoint at 1 year will assess waning. Analyses 
will take baseline measurements into account.
Outcomes
Primary outcomes, assessed in all participants, will be
1. BCG: BCG- specific IFN-γ ELISpot response 8 weeks 
post- BCG immunisation: this response is associated 
with decreased risk of tuberculosis disease postimmu-
nisation in infants.60
2. YF- 17D: neutralising antibody titres (plaque- reduction 
neutralisation test) 4 weeks post- YF immunisation.
3. Ty21a: Salmonella typhi lipopolysaccharide- specific 
IgG concentration 4 weeks post- Ty21a immunisation.
4. HPV: IgG specific for L1- proteins of HPV-16/18 
4 weeks post- HPV priming immunisation.
5. Td: tetanus and diphtheria toxoid- specific IgG concen-
tration 4 weeks post- Td immunisation.
Secondary outcomes, assessed in all participants, will 
further investigate estimates of protective immunity (for 
vaccines where these are available) and dynamics of the 
vaccine responses, as well as the impact of interventions 
on parasite clearance.
1. Protective immunity. Proportions with protective neutral-
ising antibody (YF); protective IgG levels (TT)61; sero-
conversion rates (Ty21a) 4 weeks postimmunisation.
2. Response waning. Primary outcome measures (all vac-
cines) repeated at week 52, and area under the curve 
analyses. Parasites may accelerate,58 and interventions 
delay, waning.
3. Priming versus boosting. Effects on priming versus boost-
ing will be examined for HPV, comparing outcomes 
4 weeks after the first and second vaccine doses.
Our sample collection will offer opportunities for an 
array of exploratory immunological evaluations, focusing 
on vaccine antigen specific outcomes. Exploratory assess-
ments will provide detail on immune response charac-
teristics over the study time- course, and on the role of 
immunological profiles and trans- kingdom effects in 
mediating modulation of vaccine- specific responses.
Sample size
Our sample size estimates focus on primary outcomes for 
the main comparisons for objectives i, ii and iv.
Figure 4 Outline of immunisations and interventions.1Primary endpoints will be at 8 weeks post- BCG and 4 weeks postyellow 
fever (YF- 17D), oral typhoid (Ty21a), human papilloma virus and tetanus/diptheria vaccination.2Primary endpoint for responses 
to td given at 28 weeks. BCG, Bacillus Calmette- Guérin.
 on M









pen: first published as 10.1136/bm





7Nkurunungi G, et al. BMJ Open 2021;11:e040425. doi:10.1136/bmjopen-2020-040425
Open access
Based on literature,5 60 62 we anticipate SDs of primary 
outcome measures lying between 0.3 and 0.6 log10; 
responses in rural, high- parasite settings 0.3–0.4 log10 
smaller than in the urban setting63 64 and effective treat-
ment restoring responses by approximately 0.2 log10.
63 
We, therefore, power our study to detect differences 
of this magnitude (0.2 log10) or smaller. We assume S. 
mansoni prevalence of >80% in the high- schistosomiasis 
setting47 and malaria infection prevalence of >60% in the 
high- malaria setting.
Our planned sample sizes are as follows:
High- schistosomiasis setting (objective i, trial A): 480 
(240 quarterly PZQ, 240 annual PZQ); of whom we antici-
pate 384 will be S. mansoni infected, giving 192 participants 
in each trial arm with S. mansoni infection at baseline.
High- malaria setting (objective i, trial B): 640 (320 DP, 
320 placebo) of whom we anticipate 384 will be malaria 
infected, giving 192 participants with malaria in each trial 
arm at baseline.
Urban setting (objective ii, trial C): 300 EMaBS 
participants (150 BCG ‘preimmunisation’, 150 no BCG 
immunisation).
Urban versus rural and urban versus island compar-
isons (objective iv): 150 urban EMaBS, 240 rural high- 
schistosomiasis control group participants and 320 rural 
high- malaria control group participants will be included. 
Allowing 20% lost to follow- up in rural cohorts and 10% 
in the EMaBS cohort, this will give >80% power to detect 
a difference of 0.14log10 or more in vaccine responses 
in urban compared with each rural setting at 5% signifi-
cance level assuming vaccine response SD of 0.4log10.
Table 2 shows power estimates for objective i, ii and 
iv. Sample size considerations for additional analyses 
are detailed in the protocol papers for the individual 
trials (bmjopen-2020-040426, bmjopen-2020-040427 and 
bmjopen-2020-040430).
Approach to trial objectives
Approaches to objective i (trials A and B) and objective 
ii (trial C) are detailed in the focused papers for these 
trials (bmjopen-2020-040426, bmjopen-2020-040427 and 
bmjopen-2020-040430). Here we present approaches to 
objectives iii–vi.
Objective iii: life course exposures that influence vaccine 
responses in adolescence (Trial C)
Data collected in the EMaBS over the participants’ life 
course (and as part of this protocol) will be used in regres-
sion analyses to investigate associations between infection 
exposure in utero, infancy, childhood and adolescence 
on vaccine responses. Sociodemographic variables will 
be considered as potential confounders. We will include 
the following important variables: age, sex, sociodemo-
graphic variables, BCG strain received at birth (and other 
vaccines received), helminth- related exposures, malaria 
and documented illness events.
Regression analyses will be used to evaluate associa-
tions between infections and outcomes, with adjustment 
for confounders. We will use a hierarchical statistical 
modelling approach, so that for analysis of early life 
exposures we will not adjust for later life exposures 
that may be on the causal pathway, but for associations 
Table 2 Power estimates for objectives I, II and iv (5% significance level)
SD (log10)
Log10 difference
0.08 0.10 0.12 0.14 0.16 0.18 0.20
Objective i: 192 high intensity vs 192 low intensity (infected only)
  0.3 65% 83% 94% 98% >99% >99% >99%
  0.4 42% 59% 75% 87% 94% 98% 99%
  0.5 29% 42% 56% 69% 80% 88% 94%
  0.6 21% 31% 42% 53% 65% 75% 83%
Objective ii: 150 BCG ‘preimmunisation’ vs 150 no BCG vaccination
  0.3 59% 78% 91% 97% 99% >99% >99%
  0.4 37% 53% 69% 82% 91% 96% 98%
  0.5 26% 37% 50% 63% 75% 84% 91%
  0.6 19% 28% 37% 48% 59% 69% 78%
Objective iv: 240 rural vs 150 urban*
  0.3 66% 84% 94% 99% >99% >99% >99%
  0.4 43% 60% 76% 87% 94% 98% 99%
  0.5 30% 43% 57% 80% 81% 89% 94%
  0.6 22% 32% 43% 54% 66% 76% 84%
Cells highlighted in grey correspond to >80% power.
*Numbers shown for rural high schistosomiasis versus urban setting. Power will be greater for rural high malaria versus urban setting.
BCG, bacillus calmette- guérin.
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between later childhood or current exposures and 
vaccine responses we will adjust for early life exposures 
as potential confounders. Linear regression will be used 
for the primary outcomes and for continuous secondary 
outcomes. Outcome distributions are likely to be posi-
tively skewed; where necessary, we will apply log transfor-
mations to normalise outcome distributions before linear 
regression analysis. Logistic regression will be used for 
the protective immunity secondary outcomes, which are 
binary. We shall also investigate whether multiple infec-
tion exposures combine multiplicatively in their effect 
and test for interaction.
Genetic factors will also be considered: genetic data is 
already available for EMaBS based on earlier approvals for 
work on genetic polymorphisms and vaccine responses 
in infancy. It will be of interest to determine whether 
genetic factors also have a strong influence on adoles-
cents’ responses.
Objective iv: urban–rural comparisons in vaccine response
We hypothesise that environmental (especially para-
site) exposures are key drivers of POPVAC. Hence, we 
predict differences between urban and rural settings 
within Uganda (with urban vaccine responses stronger, as 
observed in Gabon8 9 and Senegal64 and that these differ-
ences will be related to parasite exposure.
The key exposure for this objective is ‘setting’. We will 
compare outcomes between urban EMaBS and (1) rural 
high- schistosomiasis and (2) rural high- malaria partic-
ipants. For these comparisons we shall include in the 
analysis only the urban EMaBS participants who were 
randomised to receive BCG ‘preimmunisation,’ such 
that their immunisation schedule is identical to that 
in the other two settings. We will include only control 
groups from the rural high- schistosomiasis and high- 
malaria settings, since these will have received minimal 
anti- parasite treatment (figures 3 and 4). In the primary 
analysis, we will adjust for age and sex, but not for factors 
likely to be on the causal pathway between setting and 
vaccine response.
Although our settings are purposely chosen based on 
parasite prevalence, there will be overlap in this, and 
other, exposures. Therefore, we will undertake explor-
atory analyses using causal mediation modelling, a statis-
tical approach which aims to identify factors that mediate 
an observed association65 (here, between setting and 
vaccine response). We will focus on current S. mansoni 
and Plasmodium falciparum infection, and prior expo-
sure (assessed by anti- schistosome and antimalaria anti-
body), as key potential mediators of interest (see online 
supplemental figure 1). Explanatory factors for urban 
versus rural setting, and for vaccine responses, will be 
included in the causal diagram and adjusted for in anal-
yses. Although nutrition may impact vaccine responses,66 
we expect this to be less important in healthy adolescents 
than might be the case in young children; however, data 
on anthropometric parameters and diet will be collected 
and adjusted for.
One limitation is that observational analyses of parasite 
effects are beset with potential unmeasured confounding 
factors. Results will be interpreted cautiously and objec-
tive i (trials A and B) will address causality rigorously. 
The sample archive will allow future investigation of addi-
tional potential mediators. Another potential limitation 
is that in Uganda, rural to urban migration for schooling 
is common. However, in the EMaBS birth cohort we have 
data on residence. Urban to rural migration for schooling 
is relatively unlikely but will be documented.
With objective iv, we expect to confirm differences 
in vaccine responses between settings; and to obtain 
insights into environmental factors that mediate this. By 
addressing the portfolio of vaccines and array of outcomes 
presented above, we will identify categories of vaccine 
most affected; we will distinguish effects on waning and 
(for HPV) on priming versus boosting. Vaccine response 
data from urban EMaBS adolescents will provide a refer-
ence, suggesting the extent to which changes in infection 
exposure and lifestyle are likely to influence responses to 
vaccines (and to infectious diseases) as Africa’s urbanisa-
tion advances.
Objective v: the role of ‘transkingdom’ interactions in determining 
vaccine responses
We will address the hypothesis that parasites also impact 
vaccine responses through ‘transkingdom’ effects, medi-
ated by other components of the host ecosystem. We 
propose that herpesvirus activation and MT are likely to 
be determinants of vaccine response, and they are driven 
by parasitic infections. Samples from selected participants 
from each setting and study arm will be examined. To 
optimise the precision of our comparisons these will be 
selected among those (for the high- schistosomiasis and 
high- malaria settings) who had the parasitic infection of 
interest at baseline (and, if possible, no other parasitic 
infection detected) and complied with the intended treat-
ment. To test our hypothesis, we will measure markers of 
viral activation and MT in plasma/serum and/or stool. 
Initial analyses (figure 5) will investigate associations 
between these markers and vaccine responses (arrow F); 
and between settings (arrow D) or parasite infection and 
treatment (arrow E) and viral activation or MT. Objective 
vi will link herpesvirus activation, MT and parasitic infec-
tions to immune activation and regulation.
Objective vi: preimmunisation immunological parameters
There is strong evidence that preimmunisation immuno-
logical status impacts vaccine responses5 60 but the factors 
that determine this status have not been identified. We 
hypothesise that the environmental, parasitic, viral and 
microbial exposures addressed in objectives i–v are key 
(figure 5). We aim to investigate this by identifying immu-
nological parameters that specifically link the distal expo-
sures to vaccine response. These include the circulating 
cytokine and chemokine milieu, innate cell responses 
(which govern adaptive responses), and frequencies 
and phenotypes of both innate and adaptive cells. Our 
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principal focus will be on pre- immunisation measure-
ments although, in selected groups of most interest, it 
will also be possible to examine samples obtained post- 
immunisation to identify which biomarkers or cell popu-
lations change.
Initial analyses will confirm hypothesised, and identify 
new, preimmunisation immunological parameters associ-
ated with responses to vaccines in our portfolio (figure 5, 
arrow J). If we observe associations between rural versus 
urban location (arrow B) or parasites and their treat-
ment (arrow C) and vaccines responses, we will explore 
whether these effects are mediated by viral and MT vari-
ables and preimmunisation immune profiles using causal 
mediation analyses.65
Operational considerations
A programme steering committee has been set up to 
guide progress across all projects. A data and safety moni-
toring board has also been appointed to provide real- time 
safety oversight. Details of these and other operational 
activities can be found in online supplemental material 1.
Ethics and dissemination
Ethical and regulatory approval has been granted 
from the Research Ethics Committees of Uganda Virus 
Research Institute and the London School of Hygiene 
and Tropical Medicine, the Uganda National Council for 
Science and Technology and the Uganda National Drug 
Authority; details are given in online supplemental mate-
rial 1 and in each trial paper. Given the importance of 
the data and sample archive as a resource for mechanistic 
studies on the determinants of vaccine responses, assent 
and consent processes will include storage of samples 
for future and genetic studies, and anonymised data 
and sample sharing. Any protocol amendments will be 
submitted to ethics committees and regulatory bodies for 
approval before implementation.
Study findings will be published through open access 
peer- reviewed journals, presentations at local, national 
and international conferences and to the local commu-
nity through community meetings. Anonymised partic-
ipant level datasets generated will be available on 
request.
Figure 5 Synthesised analysis of study objectives. Red arrows represent our principal hypotheses. Arrows A–C are considered 
in objectives I and iv; Arrows D–F in objective v; Arrows G–J, in objective vi; as well as the fully synthesised analysis.
 on M









pen: first published as 10.1136/bm





10 Nkurunungi G, et al. BMJ Open 2021;11:e040425. doi:10.1136/bmjopen-2020-040425
Open access 
Patient and public involvement
Concepts involved in this work have been discussed with 
colleagues at the Vector Control Division and EPI in the 
Ministry of Health (Uganda) and with relevant District 
Councils, community leaders and Village Health Teams. 
We also have held meetings to explain the proposed work 
to teachers, parents, participants and village members, 
and to address their questions. Study findings will be 
shared with these stakeholders.
Data management and analysis
Sociodemographic information and clinical and labora-
tory measurements will be recorded and managed using 
Research Electronic Data Capture tools,67 68 with paper- 
based forms as back- up. All data will be recorded under 
a unique study ID number. When paper forms must be 
used, data will be entered in a study- specific database, with 
standard checks for discrepancies. All data for analysis 
will be anonymised and stored on a secure and password- 
protected server, with access limited to essential research 
personnel. Anonymised participant- level datasets gener-
ated will be available for sharing on request.
DISCUSSION
This will be the first well- powered set of studies to investi-
gate effects of schistosomiasis and malaria treatment, and 
of BCG revaccination, on vaccine responses in adoles-
cents. The results will add to understanding of POPVAC 
and of interventions that may enhance them. The sample 
archives developed will provide a major asset for explo-
ration of new leads arising from this hypothesis- driven 
work, or for an alternative, ‘systems biology’ approach 
investigating, for example, transcriptome, microbiome 
and virome.
Our focus is on the immunological effects of infection 
exposure in human participants. By understanding these 
effects, we aim to inform and promote vaccine design 
tailored to the challenging environment of LICs, and 
to inform the development of public health strategies 
(such as tailored immunisation regimens and combined 
parasite- control/immunisation interventions) that will 
optimise vaccine implementation in parasite- endemic 
settings.
Our strong immunoepidemiological design and nested 
immunological studies will address specific hypotheses 
regarding pathways of effects. Population immunology is 
useful for translation of findings to and from basic (espe-
cially animal) studies to human health. Our randomised 
design will determine causal, and reversible, effects of 
parasitic infections. Substantial sample sizes are needed 
because immune responses are highly variable in human 
populations.
We have several reasons for studying vaccine responses 
particularly among adolescents. In this study setting, they 
bear a heavy parasite burden.69 As well, this age group is 
a target group for vaccines against tuberculosis and sexu-
ally transmitted infections (currently HPV—in future, 
it is hoped, for vaccines against HIV) and for booster 
immunisations. Also, they enter a period of increased 
risk of pulmonary tuberculosis after the relatively low- risk 
period of mid- childhood, and are thus a target group for 
improved vaccines for tuberculosis.
Study timeline
POPVAC A began recruiting in July 2019. Intervention 
will be up to 12 months, with completion of the project 
scheduled for September 2020. POPVAC B is scheduled 
begin recruiting in February 2021. Intervention will be up 
to 12 months, with completion of the project scheduled 
for April 2022. POPVAC C is scheduled to begin recruiting 
in May 2020. Intervention will be up to 12 months, with 
completion of the project scheduled for April 2022.
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